Richard D Carvajal

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma
    Richard D Carvajal
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Eur J Cancer 50:2099-107. 2014
  2. ncbi Melanoma mutagenesis and aberrant cell signaling
    Danielle M Bello
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Control 20:261-81. 2013
  3. pmc Ipilimumab for patients with advanced mucosal melanoma
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 18:726-32. 2013
  4. ncbi Mucosal melanoma: a clinically and biologically unique disease entity
    Richard D Carvajal
    Department of Medicine, Melanoma Sarcoma Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Natl Compr Canc Netw 10:345-56. 2012
  5. pmc A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Pancreatology 9:404-9. 2009
  6. pmc KIT as a therapeutic target in metastatic melanoma
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 305:2327-34. 2011
  7. pmc A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Mark A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Chemother Pharmacol 66:1113-21. 2010
  8. ncbi Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
    Patrick A Ott
    Department of Medical Oncology, New York University School of Medicine, New York, NY, USA
    Invest New Drugs 31:425-34. 2013
  9. ncbi Selecting patients for KIT inhibition in melanoma
    Richard D Carvajal
    Melanoma Sarcoma Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Methods Mol Biol 1102:137-62. 2014
  10. ncbi Prognosis of acral melanoma: a series of 281 patients
    Danielle M Bello
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:3618-25. 2013

Detail Information

Publications32

  1. ncbi A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma
    Richard D Carvajal
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Eur J Cancer 50:2099-107. 2014
    ....
  2. ncbi Melanoma mutagenesis and aberrant cell signaling
    Danielle M Bello
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Control 20:261-81. 2013
    ..However, recent evidence suggests that melanoma comprises a group of diseases characterized by distinct molecular mutations. These mutations affect disease behavior but provide unique opportunities for targeted therapy...
  3. pmc Ipilimumab for patients with advanced mucosal melanoma
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 18:726-32. 2013
    ..Durable responses to ipilimumab were observed, but the overall response rate was low. Additional investigation is necessary to clarify the role of ipilimumab in patients with mucosal melanoma. ..
  4. ncbi Mucosal melanoma: a clinically and biologically unique disease entity
    Richard D Carvajal
    Department of Medicine, Melanoma Sarcoma Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Natl Compr Canc Netw 10:345-56. 2012
    ..Furthermore, the distinct clinical features and management implications unique to melanoma arising from the mucosal surfaces of the head and neck, the anorectal region, and the female genital tract are highlighted...
  5. pmc A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Pancreatology 9:404-9. 2009
    ..This phase II study was designed to further define the efficacy and toxicity of this regimen in patients with previously treated PC...
  6. pmc KIT as a therapeutic target in metastatic melanoma
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 305:2327-34. 2011
    ..We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease...
  7. pmc A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Mark A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Chemother Pharmacol 66:1113-21. 2010
    ..The cyclin-dependent kinase inhibitor flavopiridol increases irinotecan- and fluorouracil-induced apoptosis. We conducted a phase I trial of FOLFIRI + flavopiridol in patients with advanced solid tumors...
  8. ncbi Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
    Patrick A Ott
    Department of Medical Oncology, New York University School of Medicine, New York, NY, USA
    Invest New Drugs 31:425-34. 2013
    ..Although no RECIST responses were observed, the encouraging rate of SD in uveal melanoma patients indicates that it may be worthwhile to evaluate ADI-PEG 20 in this melanoma subgroup...
  9. ncbi Selecting patients for KIT inhibition in melanoma
    Richard D Carvajal
    Melanoma Sarcoma Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Methods Mol Biol 1102:137-62. 2014
    ....
  10. ncbi Prognosis of acral melanoma: a series of 281 patients
    Danielle M Bello
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:3618-25. 2013
    ..Acral melanoma (AM) is an unusual malignancy with poor survival. This study defines a cohort of patients, treated at a single institution, and the factors associated with survival and comparison with nonacral cutaneous melanoma (NACM)...
  11. pmc Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma
    Federica Catalanotti
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2257-64. 2013
    ..Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated...
  12. doi Therapeutic implications of KIT in melanoma
    Michael A Postow
    Memorial Sloan Kettering Cancer Center, Melanoma Sarcoma Division, New York, NY 10065, USA
    Cancer J 18:137-41. 2012
    ..Current efforts are investigating additional agents that target KIT and testing KIT inhibitors in combination with other agents to improve the outcome for patients with this genetic subset of melanoma...
  13. pmc The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial
    Jason J Luke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2638-47. 2012
    ..As such, we explored the potentiation of doxorubicin by flavopiridol in sarcoma, in vitro and in vivo, and conducted a phase I trial of flavopiridol with doxorubicin in patients with advanced sarcomas...
  14. pmc A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
    Mark Andrew Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Invest New Drugs 29:1004-12. 2011
    ..We developed an intermittent oral pulse-dose schedule of V to increase serum levels. We combined V with the cyclin dependent kinase inhibitor flavopiridol (F) which increases V-induced apoptosis...
  15. pmc A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors
    Mark A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 17:2484-92. 2011
    ..Production of S1P is catalyzed by sphingosine kinase 1 (SphK). Safingol, (l-threo-dihydrosphingosine) is a putative inhibitor of SphK. We conducted a phase I trial of safingol (S) alone and in combination with cisplatin (C)...
  16. pmc Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival
    Geoffrey Y Ku
    Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 116:1767-75. 2010
    ..The authors report on advanced refractory melanoma patients treated in a compassionate use trial of ipilimumab at the Memorial Sloan-Kettering Cancer Center...
  17. pmc Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
    Dana Rathkopf
    Genitourinary Oncology Service, Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7405-11. 2009
    ..Preclinical data indicate that flavopiridol enhances oxaliplatin- and fluorouracil (5FU)-induced apoptosis in a sequence-dependent manner...
  18. ncbi Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial
    Richard D Carvajal
    Memorial Sloan Kettering Cancer Center, New York, New York2Weill Medical College of Cornell University, New York, New York
    JAMA 311:2397-405. 2014
    ..Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation...
  19. ncbi Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    Suzanne L Topalian
    Suzanne L Topalian, William H Sharfman, Julie R Brahmer, Evan J Lipson, Janis M Taube, and Drew M Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Mario Sznol and Harriet M Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale New Haven Hospital, New Haven, CT David F McDermott, Beth Israel Deaconess Medical Center Donald P Lawrence, Massachusetts General Hospital Cancer Center F Stephen Hodi, Dana Farber Cancer Institute, Boston, MA Richard D Carvajal, Memorial Sloan Kettering Cancer Center, New York, NY Michael B Atkins, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC John D Powderly, Carolina BioOncology Institute, Huntersville, NC Philip D Leming, The Christ Hospital Cancer Center, Cincinnati, OH Igor Puzanov and Jeffrey A Sosman, Vanderbilt University Medical Center, Nashville, TN David C Smith, University of Michigan, Ann Arbor, MI and Jon M Wigginton, Georgia D Kollia, and Ashok Gupta, School of Medical Sciences
    J Clin Oncol 32:1020-30. 2014
    ..PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whether this is associated with extended survival or maintenance of response after treatment is discontinued...
  20. pmc Anal versus rectal melanoma: does site of origin predict outcome?
    Danielle M Bello
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Dis Colon Rectum 56:150-7. 2013
    ..Anatomic site is a predictive factor in subtypes of cutaneous and mucosal melanoma...
  21. doi Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
    Gary K Schwartz
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Invest New Drugs 31:370-80. 2013
    ..In summary, barasertib was generally well tolerated, with neutropenia the most frequent and dose-limiting toxicity, irrespective of schedule. Future development of barasertib will depend on better definition of its therapeutic index...
  22. doi Characterization of computed tomography scan abnormalities in patients with biopsy-proven hepatic metastases from uveal melanoma
    Mrinali Patel
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 70 E 66th St, New York, NY 10065, USA
    Arch Ophthalmol 129:1576-82. 2011
    ..To describe the computed tomography (CT) features in patients with biopsy-proven hepatic metastases of uveal melanoma and correlate these findings with survival...
  23. doi Therapeutic implications of the emerging molecular biology of uveal melanoma
    Mrinali Patel
    Department of Medicine and Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 17:2087-100. 2011
    ....
  24. pmc Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance
    Grazia Ambrosini
    Laboratory of New Drug Development and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin Cancer Res 18:3552-61. 2012
    ....
  25. ncbi Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection
    Brian A Ginsberg
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 16:4057-65. 2010
    ..To further define the optimal vaccination strategy, we conducted a pilot clinical trial comparing i.m. injection with particle-mediated epidermal delivery (PMED)...
  26. ncbi Radiotherapy after surgical resection for head and neck mucosal melanoma
    Abraham J Wu
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Am J Clin Oncol 33:281-5. 2010
    ..To present our single-institution experience with postoperative radiotherapy for mucosal melanoma of the head and neck...
  27. doi Treatment implications of the emerging molecular classification system for melanoma
    Emanuela Romano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Oncol 12:913-22. 2011
    ..These findings suggest that prospective genotyping of patients with melanoma should be used increasingly as we work to develop new and effective treatments for this disease...
  28. ncbi Mucosal melanoma: pathogenesis, clinical behavior, and management
    Michael A Postow
    Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Curr Oncol Rep 14:441-8. 2012
    ..Significant advances in the treatment of metastatic disease have been made with novel immunotherapeutic agents, the discovery of KIT and BRAF mutations and the development of targeted agents that inhibit these oncogenic pathways...
  29. pmc Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study
    Angelo E Volandes
    General Medicine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 118:4331-8. 2012
    ..The authors tested whether an educational video on the goals of care in advanced cancer (life-prolonging care, basic care, or comfort care) helped patients understand these goals and had an impact on their preferences for resuscitation...
  30. doi Locoregional lymphadenectomy in the surgical management of anorectal melanoma
    Daniel R Perez
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:2339-44. 2013
    ..Understanding the significance of lymphatic dissemination might assist in stratifying patients for either organ preservation or radical surgery...
  31. doi Ipilimumab-induced colitis on FDG PET/CT
    Ashima Lyall
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Nucl Med 37:629-30. 2012
    ..Physicians interpreting FDG PET/CT examinations of patients treated with ipilimumab should be aware of these FDG-avid immune-mediated toxicities...
  32. ncbi Aurora kinases: new targets for cancer therapy
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:6869-75. 2006
    ....